Skye Bioscience Inc (NASDAQ:SKYE) shares, rose in value, with the stock price down by -9.18% to the previous day’s close as strong demand from buyers drove the stock to $1.43.
Actively observing the price movement in the last trading, the stock closed the session at $1.58, falling within a range of $1.41 and $1.65. The value of beta (5-year monthly) was 1.887. Referring to stock’s 52-week performance, its high was $17.65, and the low was $1.14. On the whole, SKYE has fluctuated by -28.25% over the past month.
With the market capitalization of Skye Bioscience Inc currently standing at about $44.45 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-19.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SKYE’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of SKYE currently trading nearly -13.28% and -37.95% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.43, while the 7-day volatility ratio is showing 41.50% which for the 30-day chart, stands at 21.33%. Furthermore, Skye Bioscience Inc (SKYE)’s beta value is 1.76, and its average true range (ATR) is 0.37.
A comparison of Skye Bioscience Inc (SKYE) with its peers suggests the former has fared considerably weaker in the market. SKYE showed an intraday change of -9.18% in last session, and over the past year, it shrunk by -91.17%%.
Data on historical trading for Skye Bioscience Inc (NASDAQ:SKYE) indicates that the trading volumes over the past 10 days have averaged 3.04 and over the past 3 months, they’ve averaged 657.03K. According to company’s latest data on outstanding shares, there are 30.97 million shares outstanding.
Nearly 42.09% of Skye Bioscience Inc’s shares belong to company insiders and institutional investors own 42.73% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.28 million shares as on 2025-03-31, resulting in a short ratio of 10.99. According to the data, the short interest in Skye Bioscience Inc (SKYE) stood at 1090.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 2.17 million. The stock has fallen by -49.29% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SKYE stock heading into the next quarter.
